Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis
Malthe Faurschou Wandall‐Holm(Rigshospitalet), Melinda Magyari(University of Copenhagen), Finn Sellebjerg(Danish Multiple Sclerosis Center), Tine Iskov Kopp(Frederiksberg Hospital), Karsten Thielen(Copenhagen University Hospital), Mathias Due Buron(Rigshospitalet)
Cited by 20
Related Papers
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
|CNS Drugs|2014|293
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
|JAMA Neurology|2021|237
Apparent changes in the epidemiology and severity of multiple sclerosis
|Nature Reviews Neurology|2021|209